Now Playing
Opinion|Videos|December 11, 2024
Unraveling GLP-1 Agonists and Cardiovascular Protection
Author(s)Orly Vardeny, PharmD, MS
A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved glucose metabolism, enhanced endothelial function, and potential antiatherosclerotic properties that collectively lower the risk of cardiac events.
Advertisement
Video content above is prompted by the following:
- What insights can be gathered from the study “Propensity Score-Matched Analysis of GLP-1 Agonists' Impact on Clinical Cardiovascular Outcomes in Patients With Concurrent Heart Failure and Atrial Fibrillation,” and how does propensity score matching enhance the reliability of findings from this analysis of 51,446 patients with heart failure?
- What mechanisms might explain the reduced rates of cardiac arrest and acute myocardial infarction in the GLP-1 agonist group?
- How might these findings potentially change atrial fibrillation treatment approaches for patients with heart failure?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care
2
Semaglutide Shows Promise for Steatohepatitis Resolution in MASH
3
Advancing Biomarker Testing Across GU, Lung, and Myeloma Care
4
Smart Speaker Improves Mental Health, A1C in Older Adults With Diabetes
5
